/
Infectious Disease
Sepsis
84
Pipeline Programs↗
114
Active Trials↗
41
Companies Involved↗
Sepsis is a moderately active landscape with 84 programs across 41 companies. The most active players are Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., Tianjin Chasesun Pharmaceutical Co., LTD, Bayer. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical45
Phase 13
Phase 229
Phase 37
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
69 of 74 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 74 classified programs, each share of the total. Modality classified for 94% of 84 pipeline programs.
Analysis
Trial Status
361
clinical trials
Completed166 · 46%
Recruiting59 · 16%
Unknown status46 · 13%
Not yet recruiting39 · 11%
Terminated21 · 6%
Active, not recruiting11 · 3%
Other19 · 5%
Clinical Trials
Trial Activity
361 trials
Subset-specific Metabolic Adaptation and Functional Remodeling of Gamma Delta T (γδ T) Cells in Critically Ill ICU Patients: A Single-center, Prospective, Observational Cohort Study.
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT07680816·105 enrolled
T6A Biomarker for Detection of Bacterial Infection in Newborn Infants
Recruiting·—·N/A·NCT07670624·210 enrolled
Page 1 of 25
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)